Bruce C. Cozadd Sells 1,500 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Thursday, April 1st. The stock was sold at an average price of $164.96, for a total value of $247,440.00. Following the transaction, the chief executive officer now directly owns 323,341 shares in the company, valued at approximately $53,338,331.36. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of NASDAQ JAZZ opened at $161.93 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.84 and a current ratio of 3.98. Jazz Pharmaceuticals plc has a fifty-two week low of $101.81 and a fifty-two week high of $178.64. The firm has a market capitalization of $9.12 billion, a PE ratio of 51.08, a price-to-earnings-growth ratio of 4.64 and a beta of 1.08. The stock’s 50-day simple moving average is $166.13 and its 200-day simple moving average is $156.03.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, February 23rd. The specialty pharmaceutical company reported $4.00 earnings per share for the quarter, topping the consensus estimate of $3.58 by $0.42. Jazz Pharmaceuticals had a return on equity of 20.16% and a net margin of 7.86%. The business had revenue of $665.52 million for the quarter, compared to analyst estimates of $639.83 million. During the same quarter last year, the company earned $4.42 EPS. The business’s quarterly revenue was up 14.4% on a year-over-year basis. On average, sell-side analysts forecast that Jazz Pharmaceuticals plc will post 10.83 earnings per share for the current fiscal year.

Several equities analysts recently issued reports on JAZZ shares. Morgan Stanley increased their target price on Jazz Pharmaceuticals from $162.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 1st. TheStreet lowered Jazz Pharmaceuticals from a “b” rating to a “c+” rating in a research note on Tuesday, March 23rd. HC Wainwright increased their target price on Jazz Pharmaceuticals from $195.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday, February 5th. SVB Leerink reissued an “outperform” rating on shares of Jazz Pharmaceuticals in a research note on Monday, March 15th. Finally, Jefferies Financial Group increased their price target on Jazz Pharmaceuticals from $209.00 to $214.00 and gave the company a “buy” rating in a research report on Wednesday, February 24th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. Jazz Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $185.61.

A number of large investors have recently added to or reduced their stakes in the stock. CWM LLC grew its stake in Jazz Pharmaceuticals by 41.0% during the 4th quarter. CWM LLC now owns 258 shares of the specialty pharmaceutical company’s stock worth $43,000 after buying an additional 75 shares during the last quarter. Captrust Financial Advisors grew its stake in Jazz Pharmaceuticals by 4.1% during the 4th quarter. Captrust Financial Advisors now owns 2,820 shares of the specialty pharmaceutical company’s stock worth $465,000 after buying an additional 110 shares during the last quarter. Kendall Capital Management grew its stake in Jazz Pharmaceuticals by 1.7% during the 4th quarter. Kendall Capital Management now owns 7,275 shares of the specialty pharmaceutical company’s stock worth $1,201,000 after buying an additional 125 shares during the last quarter. Bessemer Group Inc. grew its stake in Jazz Pharmaceuticals by 9.1% during the 4th quarter. Bessemer Group Inc. now owns 1,912 shares of the specialty pharmaceutical company’s stock worth $316,000 after buying an additional 159 shares during the last quarter. Finally, NEXT Financial Group Inc purchased a new position in Jazz Pharmaceuticals during the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 95.67% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca.

Read More: Why is insider trading harmful?

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.